Cwm LLC acquires 253 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Cwm LLC increased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 62.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 657 shares of the company’s stock after purchasing an additional 253 shares during the period. Cwm LLC’s holdings in Rhythm Pharmaceuticals were worth $27,000 at the end of the most recent reporting period.

Other large investors have recently bought and sold shares of the company. AJOVista LLC purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter valued at about $42,000. Quarry LP bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at approximately $69,000. ZRC Wealth Management LLC boosted its holdings in Rhythm Pharmaceuticals by 392.8% in the first quarter. ZRC Wealth Management LLC now owns 1,971 shares of the company’s stock worth $85,000 after buying an additional 1,571 shares in the last quarter. Strs Ohio bought a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $137,000. Finally, Old Well Partners LLC bought a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $211,000.

Insider trading at Rhythm Pharmaceuticals

In other news, insider Joseph Shulman sold 10,468 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $53.00, for a total transaction of $554,804.00. Following the transaction, the insider now directly owns 30 shares of the company’s stock, valued at $1,590. The sale was disclosed in a legal filing with the SEC, which is available on the SEC’s website. In related news, insider Pamela J. Cramer sold 49,006 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $45.15, for a total transaction of $2,212,620.90. Following the sale, the insider now directly owns 13,500 shares in the company, valued at $609,525. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Joseph Shulman sold 10,468 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $53.00, for a total value of $554,804.00. Following the completion of the sale, the insider now owns 30 shares in the company, valued at $1,590. The disclosure for this sale can be found here. Insiders have sold 66,182 shares of company stock worth $3,101,567 over the last ninety days. Company insiders own 5.60% of the company’s shares.

Analysts on Wall Street are forecasting an increase

Several research analysts recently commented on RYTM shares. Canaccord Genuity Group dropped their target price on shares of Rhythm Pharmaceuticals from $80.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Bank of America cut Rhythm Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $49.00 to $42.00 in a research note on Wednesday. May 8. Finally, Needham & Company LLC restated a “buy” rating and set a $55.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat , the stock has an average rating of “Moderate Buy” and an average price target of $55.83.

Get the latest stock report on Rhythm Pharmaceuticals

The price performance of rhythm pharmaceuticals

Shares of RYTM stock opened at $44.19 on Friday. The company has a 50-day moving average price of $45.37 and a 200-day moving average price of $42.88. Rhythm Pharmaceuticals, Inc. it has a fifty-two week low of $20.97 and a fifty-two week high of $53.92. The stock has a market cap of $2.70 billion, a PE ratio of -9.54 and a beta of 2.04.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report ) last issued its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.16. The company had revenue of $29.08 million for the quarter, compared to the consensus estimate of $28.79 million. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The company’s revenue was up 51.3% compared to the same quarter last year. During the same period in the previous year, the company posted EPS of ($0.82). As a group, equities analysts expect that Rhythm Pharmaceuticals, Inc. to post -4.4 earnings per share for the current fiscal year.

Rhythm Pharmaceuticals Profile

(Free report)

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor-deficient obesity (LEPR), and Bardet-Biedl and Alström syndrome.

See Also

Want to see what other hedge funds own RYTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report).

Get news and ratings for Rhythm Pharmaceuticals daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com ‘s FREE daily email newsletter.